RxDoctor Payments Data

Rhuna Shen, MD

Cardiovascular Disease · Mount Arlington, NJNPI 1114089729

Payments from drug & device makers

$10,711in general payments, 2019–2025

Across 507 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$894
  • Novartis$885
  • Edwards Lifesciences$817
  • Johnson & Johnson$705
  • Abiomed$591
  • plus $5K from 43 others

What the payments were for

  • Travel & lodging$1,06410%
  • Food & beverage$9,62090%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,711 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$449,066
Medicare patients
1,643
Services billed
5,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$397,291
XareltoRivaroxaban271$311,526
JardianceEmpagliflozin160$200,717
EntrestoSacubitril/Valsartan136$176,140
FarxigaDapagliflozin Propanediol152$155,198
OzempicSemaglutide49$70,604
Repatha SureclickEvolocumab58$66,081
BrilintaTicagrelor27$30,608
LivaloPitavastatin Calcium23$19,024
Praluent PenAlirocumab13$17,244
MounjaroTirzepatide11$15,780
Metoprolol Succinate775$11,916
Dabigatran EtexilateDabigatran Etexilate Mesylate35$9,885
EdarbiAzilsartan Medoxomil11$8,017
Rosuvastatin Calcium416$7,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$295$397,291314 claims
Johnson & JohnsonXarelto$705$311,526271 claims
Boehringer IngelheimJardiance$182$200,717160 claims
AstraZenecaFarxiga, Brilinta$894$185,806179 claims
NovartisEntresto$885$176,140136 claims
Novo NordiskOzempic$374$70,60449 claims
Kowa Pharmaceuticals America, Inc.Livalo$44$19,02423 claims
Lilly USA, LLCMounjaro$120$15,78011 claims
Lexicon Pharmaceuticals, Inc.Inpefa$105$7,55711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Mount Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →